Orygen Virtual World Project: Bringing To Life A New Age Of Digitally Enhanced Youth Mental Health Services
Funder
National Health and Medical Research Council
Funding Amount
$396,423.00
Summary
Providing mental health care to young people is essential as we know that most mental health problems begin before the age of 25. Harnessing technologies to connect young people to youth mental health (YMH) services remotely has enormous potential to improve access and engagement. The project aims to design a unique virtual world or 'clinic' with the help of young people with lived experience and then test three types of therapy to see if they are liked by young people and feasible to deliver.
Design And Engineering Of Adnectins For Diagnosis And Therapy
Funder
National Health and Medical Research Council
Funding Amount
$803,152.00
Summary
This project aims to engineer a naturally-occurring human protein, called an adnectin, to produce molecules that are able to bind specific targets in the human body, and as such may be used in the diagnosis and therapy of a range of diseases.
Ketamine Therapy Among Patients With Treatment-resistant Depression: A Randomised, Double-blind, Placebo-controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,069,382.00
Summary
In the last decade, there have been reports of powerful antidepressant effects after a single injection of anaesthetic ketamine, with dramatic (though shortlasting) effects within 24 hours. This will be the first controlled study to test whether a course of repeated ketamine treatments, given over 4 weeks, is effective and safe in treating depression.
A Course Of Oxytocin Nasal Spray To Improve Social Communication In Young People With Autism
Funder
National Health and Medical Research Council
Funding Amount
$293,735.00
Summary
Autism is characterised by impairments in social behaviour and communication, and is a cause of major lifelong disability. A novel intervention, Oxytocin, enhances social communication in autism and non-clinical populations. This project will determine whether Oxytocin, taken twice daily over 8 weeks, improves social interaction skills in everyday life for young people with autism. This project represents a crucial step in developing a novel and effective new treatment for Autism.
The Effects Of Oxytocin Nasal Spray On Mechanisms Of Social-communication In Young People With Autism
Funder
National Health and Medical Research Council
Funding Amount
$191,400.00
Summary
Autism is charcterised by deficits in social behaviour and communication, and is a cause of major lifelong disability. A novel intervention, Oxytocin, enhances social communication in non-clinical populations. This project will determine whether OT improves social communication deficits characteristic of autism. This project is a critical first step towards treating a core deficit of autism.
Combating Bacterial ‘superbugs‘ By Innovative Dosing Strategies That Combine Available Antibiotics To Prevent Resistance
Funder
National Health and Medical Research Council
Funding Amount
$547,694.00
Summary
As resistant bacterial ‘superbugs’ are among the 3 most serious threats to global health and as new antibiotics are lacking, innovative strategies to prevent bacterial resistance are urgently needed. This proposal will yield molecular insights on optimal combinations of current beta-lactam antibiotics to maximise bacterial killing without resistance. This project will provide guidance to physicians on how to optimally combine available beta-lactam antibiotics to prevent bacterial resistance.
Throughout our lives cells must die and be replenished. One way multicellular organisms remove unwanted cells is through a process called programmed cell death. This process eliminates redundant, damaged or infected cells by a program of cell suicide. We are studying the underlying molecular mechanisms of this cell suicide in order to design new pharmaceuticals to treat illnesses caused by a disruption in programmed cell death. The fine balance between living and dying cells must be maintained a ....Throughout our lives cells must die and be replenished. One way multicellular organisms remove unwanted cells is through a process called programmed cell death. This process eliminates redundant, damaged or infected cells by a program of cell suicide. We are studying the underlying molecular mechanisms of this cell suicide in order to design new pharmaceuticals to treat illnesses caused by a disruption in programmed cell death. The fine balance between living and dying cells must be maintained and if this balance is lost then disease may result. A reduced level of cell death may result in cancers while too many dying can contribute to degenerative diseases such as Alzheimer's disease and stroke. Currently many of these diseases do not have effective treatments. We will determine the three-dimensional structures of key proteins involved in programmed cell death and use this information to design drugs that can interfere with the molecular processes involved in signalling cell death. Such drugs may prove useful new therapies in a wide range of diseases caused by a breakdown in the biochemical paths to cell death.Read moreRead less
Relaxin-3 Systems In Brain: Validation Of Neural Targets And Functional Roles
Funder
National Health and Medical Research Council
Funding Amount
$537,579.00
Summary
Our laboratory recently discovered the brain 'transmitter' called 'relaxin-3', and are researching how it affects brain activity and animal physiology and behaviour. Findings suggest that relaxin-3 can modulate memory, responses to stress and other complex behaviours. Identifying the various actions of relaxin-3 in the brain could provide potential new treatments for conditions such as anxiety-depression, cognitive deficits (dementia) and schizophrenia.